Latest Regulatory Approvals News

Almonty Industries has locked in final commitments for an AUD 18.45 million equity placement from existing shareholders, aiming to strengthen its financial position and cover offer costs. The placement includes warrants and options, with closing pending regulatory approval.

Matsa Resources is poised to commence mining at its Devon Pit Gold Mine after securing all regulatory approvals and raising fresh capital. The company targets delivering its final feasibility study in the March 2025 quarter, marking a critical step toward production.

Auric Mining reports robust gold production and revenue in its December 2024 quarterly update, alongside strategic progress including a key processing plant acquisition and advancing mining projects.

Taruga Minerals reports significant progress in Western Australia with new exploration license applications and ongoing copper project developments, alongside key corporate changes and a stable cash position.

Atlantic Lithium has cleared critical regulatory hurdles for its Ewoyaa Lithium Project in Ghana, securing key permits and raising A$10 million to advance construction plans. The company also updated its feldspar resource estimate, underscoring the project's growing commercial potential.

Mako Gold Limited has agreed to a takeover by Aurum Resources, creating a stronger gold exploration entity in West Africa with over A$20 million in cash to accelerate development at key projects.

Magnum Mining and Exploration Limited moves forward with acquiring two promising rare earth element projects in Brazil while progressing negotiations on a green pig iron venture in Saudi Arabia.

Eclipse Metals Ltd reports significant progress in its Greenland rare earth projects, including access to historic drill cores and positive resource estimates, while advancing towards mining licenses and applying for EU strategic funding.

A1 Investments & Resources Ltd reports a modest cash outflow for the June 2024 quarter while actively pursuing acquisitions and planning convertible note funding to support growth.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

BlinkLab has launched its pivotal FDA registrational study for its AI-driven autism diagnostic app, BlinkLab Dx 1, following positive FDA feedback and promising preliminary results.

Icon Energy Limited reported a $455K cash balance and issued 100 million shares this quarter to sustain operations amid ongoing uncertainty over the ATP 855 permit renewal.